Elite, Prasco launch loxapine capsules

Elite's loxapine succinate capsules provide treatment for schizophrenia.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Elite Pharmaceuticals and its distribution and marketing partner Prasco are introducing loxapine capsules. 

Elite entered a license, supply, and distribution agreement with Prasco for Elite’s loxapine succinate capsules, in dosage stengths of 5 mg, 10 mg, 25 mg, and 50 mg.

The product, a generic of Loxatine, is indicated for the treatment of schizophrenia and currenlty is currently listed on the FDA drug shortage list.

Prasco will be the exclusive U.S. distributor for Loxapine capsules, which will be marketed under Burel Pharmaceutical’s label. Prasco will provide sales, marketing, and distribution for the product, and Elite will manufacture the product.

"Elite is excited to partner with Prasco to launch loxapine,” said Nasrat Hakim, president and CEO of Elite. “Prasco has the scale, infrastructure, reputation, and expertise to be an excellent partner for the distribution of this product for Elite.”

"Prasco is honored to align with Elite Pharmaceuticals in bringing much-needed supply to this critical product,” said Chris Arington, Prasco CEO. “Loxapine tablets will be made available through Prasco’s network of wholesalers and distributors to provide nationwide access for patients.”